Peter de Waele
Directeur Général chez Advanced Therapies Consulting Limited
Profil
Peter de Waele is the founder of Xcellentis NV, which was founded in 2001, where he held the title of Chief Operating Officer in 2006.
He is currently the Managing Director at Advanced Therapies Consulting Limited.
Dr. de Waele's former positions include Chief Therapeutics Officer at Fujirebio Europe NV, Assistant Professor at Ghent University in 1986, and Vice President-Research & Development at Celyad Oncology SA from 2010 to 2017.
Dr. de Waele received his graduate and doctorate degrees from Ghent University.
Postes actifs de Peter de Waele
| Sociétés | Poste | Début |
|---|---|---|
| Advanced Therapies Consulting Limited | Directeur Général | - |
Anciens postes connus de Peter de Waele
| Sociétés | Poste | Fin |
|---|---|---|
| CELYAD ONCOLOGY SA | Directeur Technique/Scientifique/R&D | - |
| Xcellentis NV | Fondateur | 01/01/2006 |
| Ghent University | Corporate Officer/Principal | 01/01/1986 |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Corporate Officer/Principal | - |
Formation de Peter de Waele
| Ghent University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| Entreprise privées | 3 |
|---|---|
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
| Xcellentis NV | Health Technology |
| Advanced Therapies Consulting Limited |
